Nymox Pharmaceutical CORP (NYMXF) — SEC Filings

Overview

Nymox Pharmaceutical CORP (NYMXF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 7, 2025: Nymox Pharmaceutical Corporation announced on November 7, 2025, that the U.S. District Court for the Central District of California granted its motion and that of Computershare Investor Services Inc. to dismiss Christopher Riley's complaint. The case was dismissed with prejudice.

Sentiment Summary

Across 13 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 8 neutral, 2 mixed. The dominant filing sentiment for Nymox Pharmaceutical CORP is neutral.

Filing Type Overview

Nymox Pharmaceutical CORP (NYMXF) has filed 11 6-K, 2 20-F with the SEC between Mar 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (13)

• Nymox Pharma Wins Lawsuit Dismissal — 6-K · Nov 7, 2025 Risk: low
  Nymox Pharmaceutical Corporation announced on November 7, 2025, that the U.S. District Court for the Central District of California granted its motion and that
• Nymox CEO Buys 102,844 Shares — 6-K · Oct 22, 2025 Risk: medium
  Nymox Pharmaceutical Corporation reports that its CEO, Dr. Paul Averback, purchased 102,844 shares of the company's stock on October 20, 2025. This transaction
• Nymox Wins Legal Battles in US and Bahamas — 6-K · Sep 23, 2025 Risk: medium
  Nymox Pharmaceutical Corporation announced on September 23, 2025, that the U.S. District Court for the Central District of California dismissed Randall Lanham's
• NYMOX Remains Revenue-Less, Pushing R&D Amid Funding Concerns — 20-F · Jun 3, 2025 Risk: high
  NYMOX PHARMACEUTICAL CORP reported no revenue for the fiscal year ended December 31, 2024, consistent with the prior two years, indicating a pre-commercial or r
• Nymox Faces Employee Complaints Amid Legal Battles — 6-K · May 22, 2025 Risk: medium
  Nymox Pharmaceutical Corporation reported on May 22, 2025, that two former employees have filed complaints against the company. These individuals are reportedly
• Nymox Dismisses Delaware Lawsuit Against AscellaHealth — 6-K · Mar 11, 2025 Risk: medium
  Nymox Pharmaceutical Corporation announced on March 11, 2025, that it dismissed a Delaware legal matter against AscellaHealth on March 7, 2025. This decision wa
• Nymox Pharma Files 6-K with Director Transaction Data — 6-K · Jan 2, 2025 Risk: low
  Nymox Pharmaceutical Corp. filed a 6-K report on January 2, 2025, detailing financial information for the period ending September 30, 2024. The filing includes
• Nymox Pharmaceutical Stock Resumes Trading on OTCQB — 6-K · Dec 17, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on December 17, 2024, that its common stock has resumed trading on the OTCQB Venture Market under the symbol NYMXF. T
• Nymox Pharma Files 20-F for FY2023 — 20-F · Aug 29, 2024 Risk: medium
  Nymox Pharmaceutical Corp. filed its 20-F for the fiscal year ending December 31, 2023. The company is involved in the development of therapeutics for enlarged
• Nymox Pharma Files 6-K Regarding 20-F Annual Report — 6-K · Jul 18, 2024 Risk: low
  Nymox Pharmaceutical Corporation announced on July 18, 2024, that it has issued a press release concerning its annual report on Form 20-F. This announcement is
• Nymox MAA Expires with Danish Medicines Agency — 6-K · Jul 16, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on July 16, 2024, that its marketing authorization application (MAA) submission to the Danish Medicines Agency (DKMA)
• Nymox Pharma Dismisses Accounting Firm TPS THAYER — 6-K · May 13, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on April 4, 2024, the dismissal of TPS THAYER, LLC as its independent registered public accounting firm. The company'
• Nymox Pharma Resolves Bahamas Litigation — 6-K · Mar 28, 2024 Risk: low
  Nymox Pharmaceutical Corporation announced on March 27, 2024, that it has secured a formal order from the Bahamas Supreme Court to resolve litigation initiated

Risk Profile

Risk Assessment: Of NYMXF's 13 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Christopher Riley
• Dr. Paul Averback
• Randall Lanham
• Mr. Riley
• Paul Averback
• James Robinson
• Patrick Doody
• Lin Dood
• James G. Robinson

Industry Context

Nymox Pharmaceutical Corp operates in the highly competitive pharmaceutical and biotechnology sector, focusing on therapeutic areas with significant unmet needs, such as urological conditions (BPH, prostate cancer) and neurodegenerative diseases (Alzheimer's). The industry is characterized by long development timelines, substantial R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing market access against established players and emerging therapies.

Top Tags

litigation (2) · bahamas (2) · legal (2) · regulatory-filing (2) · annual-report (2) · legal-win (1) · dismissal (1) · insider-buy (1) · ceo-purchase (1) · form-6k (1)

Key Numbers

• Shares Purchased: 102,844 — CEO Dr. Paul Averback's recent stock acquisition
• Revenue: $0 — for fiscal year 2024, consistent with 2023 and 2022, indicating no commercial products
• Carrying Amounts (Less than One Year): $6.35M — as of December 31, 2024, likely representing short-term liabilities or commitments
• Carrying Amounts (One to Five Years): $6.08M — as of December 31, 2024, likely representing longer-term liabilities or commitments
• Reporting Period End Date: 2024-09-30 — The filing covers financial information up to this date.
• Filing Date: 2025-01-02 — The date the 6-K was submitted to the SEC.
• Assets: 6428000 — Total assets as of December 31, 2023.

Related Companies

NYMX

Frequently Asked Questions